Cadence Capital Management’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
– Sell
-132,414
Closed -$2.71M – 449
2019
Q1
$2.71M Sell
132,414
-74,900
-36% -$1.3M 0.24% 112
2018
Q4
$2.61M Buy
207,314
+80,023
+63% +$1.19M 0.26% 102
2018
Q3
$1.95M Sell
127,291
-39,999
-24% -$553K 0.11% 271
2018
Q2
$2.19M Sell
167,290
-8,584
-5% -$94.5K 0.13% 207
2018
Q1
$1.44M Buy
175,874
+5,507
+3% +$44.6K 0.09% 310
2017
Q4
$1.51M Buy
170,367
+12,265
+8% +$113K 0.1% 283
2017
Q3
$1.76M Buy
158,102
+7,683
+5% +$74.8K 0.11% 219
2017
Q2
$1.35M Buy
150,419
+8,241
+6% +$65.4K 0.09% 277
2017
Q1
$1.12M Buy
142,178
+6,015
+4% +$49K 0.08% 313
2016
Q4
$1.17M Buy
136,163
+3,498
+3% +$30K 0.08% 312
2016
Q3
$1.09M Buy
132,665
+43,970
+50% +$369K 0.08% 289
2016
Q2
$713K Sell
88,695
-31,520
-26% -$253K 0.05% 379
2016
Q1
$810K Buy
+120,215
New +$791K 0.06% 354
2014
Q4
– Sell
-156,050
Closed -$813K – 635
2014
Q3
$813K Buy
+156,050
New +$802K 0.04% 439

Other funds holding NEO

Cadence Capital Management's NEO Position: Q2 2019 in Review

Cadence Capital Management sold out of NeoGenomics (NEO) in Q2 2019, closing a stake of 132,414 shares — an estimated $2.71M sold.

Cadence Capital Management first reported a position in NEO in Q3 2014 and held it in 14 quarters. The position peaked at $2.71M in Q1 2019. 253 funds tracked by Wall St. Rank hold NEO as of Q2 2019.

  • Cadence Capital Management reported no remaining NeoGenomics position as of Q2 2019 after selling out during the quarter.
  • Cadence Capital Management sold 132,414 NeoGenomics shares in Q2 2019, an estimated $2.71M.
  • Cadence Capital Management first reported a position in NeoGenomics in Q3 2014 and held it in 14 quarters.
  • Cadence Capital Management's NeoGenomics position peaked at $2.71M in Q1 2019.
  • 253 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2019.

Based on Cadence Capital Management's 13F filing for Q2 2019, filed 12 Aug 2019.